Neuroimmun GmbH

Neuroimmun GmbH is a German diagnostics company based in Karlsruhe that develops enzyme-linked immunosorbent assay (ELISA) systems for measuring biogenic amines and amino acids, and for novel biomarkers associated with neuro-inflammation, cancer, cardiovascular disease and gastroenterological inflammatory conditions. The company's public identity is built around a proprietary, patented method for the quick and efficient modification of biogenic amines and amino acids so that they can be measured in ELISAs; the company describes the system as simple and adaptable to automated devices. The business traces its origins to 1998, when it was founded as an R&D consulting company, with assay development beginning in 2008. The present operating company, Neuroimmun GmbH, was established in 2016 by Dr. Karl-Heinz Kellner, who has been developing immunoassays for biogenic amines and amino acids since 2006. The company is headquartered at Unterweingartenfeld 6 in Karlsruhe and is registered under HRB 724749 with German VAT ID 35105/15627. Neuroimmun's stated mission is the development of diagnostic methods for novel innovative biomarkers in neuro-inflammation, cancer, cardiovascular and gastroenterological inflammatory diseases. It aims to provide biomarkers that indicate susceptibility to specific diseases, thereby enabling the monitoring of prevention and intervention strategies. Rather than selling directly into many markets itself, the company works with a distribution partner: Immundiagnostik AG of Bensheim, Germany, a globally operating diagnostics company represented in over 70 countries worldwide. As a privately held, founder-led diagnostics developer, Neuroimmun occupies a specialist niche in the life-sciences tools and in-vitro diagnostics space, focusing on assay chemistry and biomarker research rather than high-volume consumer testing. Its products and know-how are aimed at research and clinical laboratory customers interested in neuro-immunological and inflammatory biomarkers.

Neuroimmun GmbH's history is closely tied to the work of Dr. Karl-Heinz Kellner, who has been developing immunoassays for biogenic amines and amino acids since 2006. According to the company's own account, the underlying business was founded in 1998 as an R&D consulting company, and assay development began in 2008. During this period Dr. Kellner developed and patented a quick and easy method for the efficient modification of biogenic amines and amino acids so that they could be measured in ELISAs. The company describes this system as simple and adaptable to automated devices. The present legal entity, Neuroimmun GmbH, was established in 2016 by Dr. Kellner. It is based in Karlsruhe, Germany, at Unterweingartenfeld 6, and is registered under HRB 724749 with VAT ID 35105/15627. The company's mission is the development of diagnostic methods for novel innovative biomarkers in neuro-inflammation, cancer, cardiovascular and gastroenterological inflammatory diseases. To realize this mission, Neuroimmun provides biomarkers that indicate susceptibility to specific diseases, enabling the monitoring of prevention and intervention strategies. For market reach, Neuroimmun relies on a distribution partnership with Immundiagnostik AG of Bensheim, Germany, a globally operating diagnostics company represented in over 70 countries worldwide. This partnership allows the Karlsruhe-based developer to reach international research and clinical laboratory customers without building a large direct sales organization of its own. The company remains privately held and founder-led, with no public listing indicated in the available evidence.

• 2016

  Neuroimmun GmbH established by Dr. Karl-Heinz Kellner.

• 2008

  Assay development starts.

• 2006

  Dr. Karl-Heinz Kellner begins developing immunoassays for biogenic amines and amino acids.

• 1998

  Business founded as an R&D consulting company.

Specialist developer of ELISA-based diagnostic assays and novel biomarkers for neuro-inflammation, cancer, cardiovascular and gastroenterological inflammatory diseases, distributed internationally through Immundiagnostik AG.

• ELISA systems for biogenic amines and amino acids

  Based on a patented method for efficient modification of biogenic amines and amino acids; simple and adaptable to automated devices.

• Biomarker assays for neuro-inflammation, cancer, cardiovascular and gastroenterological inflammatory diseases

  Diagnostic methods for novel innovative biomarkers indicating susceptibility to specific diseases.

1. 1Neuroimmun GmbH - ELISAneuroimmun.com
2. 2Neuroimmun GmbH - Companyneuroimmun.com
3. 3Neuroimmun GmbHwikidata.org